Ixabepilone Patent Expiration
Ixabepilone is Used for treating cancer, specifically breast cancer, by administering Ixabepilone in various formulations and regimens including intravenous administration and combination therapy with Capecitabine. It was first introduced by R-Pharm Us Llc
Ixabepilone Patents
Given below is the list of patents protecting Ixabepilone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ixempra Kit |
US7312237 (Pediatric) | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb 21, 2025
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7312237 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug 21, 2024
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
USRE41393 (Pediatric) | Treatment of refractory tumors using epothilone derivatives |
Aug 08, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US6670384 (Pediatric) | Methods of administering epothilone analogs for the treatment of cancer |
Jul 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US7022330 (Pediatric) | Parenteral formulation for epothilone analogs |
Jul 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | USRE41393 | Treatment of refractory tumors using epothilone derivatives |
Feb 08, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US6670384 | Methods of administering epothilone analogs for the treatment of cancer |
Jan 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7022330 | Parenteral formulation for epothilone analogs |
Jan 23, 2022
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
USRE41911 (Pediatric) | Epothilone derivatives |
Mar 28, 2021
(Expired) | R-pharm Us Llc |
| Ixempra Kit | USRE41911 | Epothilone derivatives |
Sep 28, 2020
(Expired) | R-pharm Us Llc |
| Ixempra Kit |
US7125899 (Pediatric) | Epothilone derivatives |
Nov 26, 2018
(Expired) | R-pharm Us Llc |
| Ixempra Kit | US7125899 | Epothilone derivatives |
May 26, 2018
(Expired) | R-pharm Us Llc |
Ixabepilone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ixabepilone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | National Cancer Institute (NCI) | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | M.D. Anderson Cancer Center | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2 |
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Allarity Therapeutics | NA |
TERMINATED
(Mar 1, 2026)
| PHASE2 |